Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by GAMMA Investing LLC

GAMMA Investing LLC boosted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 30,759.4% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 166,332 shares of the biopharmaceutical company's stock after purchasing an additional 165,793 shares during the quarter. GAMMA Investing LLC owned about 0.13% of Alnylam Pharmaceuticals worth $44,913,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC purchased a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at about $243,000. R Squared Ltd purchased a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at about $33,000. Chicago Partners Investment Group LLC purchased a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at about $246,000. Jennison Associates LLC purchased a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at about $61,160,000. Finally, E. Ohman J or Asset Management AB grew its holdings in Alnylam Pharmaceuticals by 13.0% in the 4th quarter. E. Ohman J or Asset Management AB now owns 6,100 shares of the biopharmaceutical company's stock valued at $1,435,000 after buying an additional 700 shares during the period. Institutional investors and hedge funds own 92.97% of the company's stock.

Analysts Set New Price Targets

Several research firms have commented on ALNY. Morgan Stanley lowered their price target on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating for the company in a report on Friday, April 11th. Canaccord Genuity Group lifted their price target on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a "buy" rating in a report on Friday, March 21st. Citigroup lifted their price target on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a "buy" rating in a report on Friday, March 21st. Redburn Atlantic began coverage on Alnylam Pharmaceuticals in a report on Monday, March 31st. They issued a "buy" rating and a $353.00 price target for the company. Finally, Stifel Nicolaus lifted their price target on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a "buy" rating in a report on Monday, March 31st. One analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $319.17.

Alnylam Pharmaceuticals Stock Up 0.9%

Alnylam Pharmaceuticals stock traded up $2.69 during midday trading on Thursday, hitting $308.00. 761,194 shares of the company were exchanged, compared to its average volume of 929,505. The company's fifty day moving average price is $262.51 and its 200-day moving average price is $256.16. The company has a market cap of $40.16 billion, a PE ratio of -141.93 and a beta of 0.17. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $147.25 and a fifty-two week high of $310.23.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The business had revenue of $594.19 million during the quarter, compared to the consensus estimate of $584.32 million. During the same quarter last year, the firm posted ($0.16) earnings per share. The firm's quarterly revenue was up 20.2% compared to the same quarter last year. On average, research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 31,640 shares of the company's stock in a transaction on Friday, May 30th. The stock was sold at an average price of $304.39, for a total transaction of $9,630,899.60. Following the completion of the transaction, the chief executive officer now directly owns 48,948 shares in the company, valued at $14,899,281.72. This represents a 39.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.50% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.